Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The University of Pennsylvania Uterus Transplant for Uterine Factor Infertility Trial (UNTIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03307356
Recruitment Status : Enrolling by invitation
First Posted : October 11, 2017
Last Update Posted : October 13, 2021
Sponsor:
Information provided by (Responsible Party):
University of Pennsylvania

Tracking Information
First Submitted Date  ICMJE October 5, 2017
First Posted Date  ICMJE October 11, 2017
Last Update Posted Date October 13, 2021
Actual Study Start Date  ICMJE January 10, 2018
Estimated Primary Completion Date July 1, 2029   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 7, 2021)
  • Recipient: Successful engraftment of deceased or living donor uterus [ Time Frame: Assessed 6 months after transplant ]
    Uterus remains in recipient with no complications (i.e. infection or rejection) or any complications that did arise could be successfully treated.
  • Recipient: Live-born child per embryo transfer [ Time Frame: Assessed up to 35 weeks post-embryo transfer ]
  • Living Donor: Survival post-donation [ Time Frame: Assessed at 2 years post-hysterectomy ]
    Living or deceased
Original Primary Outcome Measures  ICMJE
 (submitted: October 10, 2017)
Successful engraftment of deceased donor uterus [ Time Frame: Assessed 12 months after transplant ]
Uterus remains in recipient with no complications (i.e. infection or rejection) or any complications that did arise could be successfully treated.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 7, 2021)
  • Recipient: Neonatal growth [ Time Frame: Assessed at birth ]
    Birth weight percentile at delivery
  • Recipient: Pregnancy complications [ Time Frame: Assessed up to 35 weeks post-embryo transfer ]
    Including but not limited to preeclampsia, gestational hypertension, gestational diabetes, and cholestasis of pregnancy.
  • Recipient: Surgical or medical complications following cesarean delivery [ Time Frame: Assessed up to 6 months after delivery ]
  • Recipient: Surgical or medical complications following hysterectomy [ Time Frame: Assessed 2 years after hysterectomy ]
  • Recipient: Child height percentile [ Time Frame: Assessed at 2 years ]
  • Recipient: Child weight percentile [ Time Frame: Assessed at 2 years ]
  • Living Donor: Intraoperative/postoperative/pregnancy/postpartum complications [ Time Frame: Assessed at 2 years post-hysterectomy ]
  • Living Donor: Symptomatic claudication of buttock or legs [ Time Frame: Assessed at 2 years post-hysterectomy ]
    yes or no
  • Living Donor: Genitourinary tract complications [ Time Frame: Assessed at 2 years post-hysterectomy ]
  • Living Donor: Need for reoperation [ Time Frame: Assessed at 2 years post-hysterectomy ]
Original Secondary Outcome Measures  ICMJE
 (submitted: October 10, 2017)
Postoperative complications [ Time Frame: Assessed 12 months after transplant ]
Including but not limited to evidence of damage to surrounding organs/vessels, need for reoperation, thromboembolic event, infection, rejection episodes (clinical and histologic), impaired renal function
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE The University of Pennsylvania Uterus Transplant for Uterine Factor Infertility Trial
Official Title  ICMJE The University of Pennsylvania Uterus Transplant for Uterine Factor Infertility Trial
Brief Summary

Options for childbearing are limited for the thousands of women in the United States who suffer from absolute uterine factor infertility. Uterine transplantation is an emerging treatment that provides hope for these individuals.

In the Penn UNTIL trial, the investigators plan to perform uterus transplants on five women who will ultimately undergo embryo transfer, pregnancy, delivery, and then transplant hysterectomy.

This trial is accepting women in need of a transplant and also women who are interested in being a live donor.

For more information please visit: https://clinicalresearch.itmat.upenn.edu/clinicaltrial/4821/congenital-abnormalitiesfemale-infertility-penn-ut/

Detailed Description

BACKGROUND The inability to conceive children can be one of the most devastating and traumatic situations to arise in the life of an individual or couple. While assisted reproductive technologies have been developed that help overcome many causes of infertility, uterine factor infertility has remained an intractable condition. Absolute uterine factor infertility (AUFI) occurs when the uterus is either not present (congenitally absent or surgically removed) or is present but is not capable of sustaining a pregnancy. AUFI can result from either congenital absence of a uterus (Mayer-Rokitansky-Kuster-Hauser [MRKH] syndrome) or other Müllerian anomalies. MRKH occurs in 1:4000 of females. It is difficult to determine the exact number of women that suffer from AUFI, however estimates are as high as 7 million women between the ages of 15-34 may suffer from this condition in the United States.

Existing options for individuals with AUFI to achieve parenthood are adoption and the use of a gestational carrier. Use of a gestational carrier is the only alternative that allows an individual or couple to have a child genetically related to the intended parent(s). These options are considered acceptable to many women with AUFI; however, there are a number of significant limitations to these alternatives. The use of a gestational carrier is fraught with ethical, legal, and social controversy because it shifts the burden of gestation from one woman to another, usually for payment. Additionally, adoption and/or surrogacy may not be permissible to a couple due to social, ethical, moral or religious considerations. If these alternatives are acceptable to a couple, they may not be affordable. Finally, these alternatives may not be accessible as barriers to domestic and international adoption have increased and the use of a compensated gestational carrier is not legally protected in most states (and is illegal in some states). The limitations of these alternatives may account for the extraordinary interest in UTx by women with AUFI, as 92% of women with AUFI would undergo UTx as first line management for their AUFI, above adoption and surrogacy.

Understanding the limitations of these alternatives, uterine transplantation (UTx) began to be explored as a concept in animal studies in the 1970s. In 2012, a Swedish team led by Dr. Mats Brannstrom started the first human uterine transplantation trial. The first live birth after successful UTx occurred in Sweden in 2014. As of September 2021, the investigators estimate 33 uterus transplants have been performed in the United States and >10 babies have been born to these women.

Unlike all other transplants, uterine transplantation is "ephemeral". This means that a uterine transplant is only maintained during the individual's child-bearing period which, in the case of uterine transplantation, will be the time necessary to produce one or two children (<10 years). Although pregnancy after transplant is considered high risk, more than 15,000 babies have been born to female recipients of solid organ transplants that were immunosuppressed with no reported increased risk of fetal malformations.

STUDY DESIGN Recognizing that the University of Pennsylvania has been a leader in all of the domains required to build a successful uterus transplant program, planning for the Penn UNTIL trial began in October 2016. The UNTIL trial is is a nonrandomized, interventional human study whose goal is to achieve live birth after donor uterus transplantation. The investigators plan to perform approximately five uterus transplants in this pilot trial. Prior to being listed for transplant, the participants will need to create embryos through ovarian stimulation, oocyte retrieval and in vitro fertilization that will be cryopreserved. After undergoing donor uterus transplantation, participants will be monitored for rejection, infection and other complications for twelve months.

If the graft is clinically stable and any complications that arise are successfully treated 6 months after transplantation, the embryos created prior to transplantation will be directly placed into the uterus in order for the women to achieve pregnancy. If pregnancy is achieved the participant will be monitored by a Maternal Fetal Medicine specialist (high-risk obstetrician) with goal to deliver at 37-39 weeks unless otherwise indicated. All deliveries will occur via cesarean delivery. If the participant and partner wish to attempt an additional pregnancy and the medical team feel it is safe to proceed, attempts at a second pregnancy will be undertaken. Again, if pregnancy is achieved following embryo transfer the participant will be monitored for the duration of her pregnancy by a Maternal Fetal Medicine specialist with goal to deliver at 37-39 weeks through repeat cesarean delivery unless otherwise indicated. Hysterectomy will either be performed at the time of cesarean delivery or shortly following the final cesarean delivery.

The transplanted uteri will be from either living or deceased donors. Interested potential donors will be screened and evaluated and if eligible with continued interest in participation, will undergo radical hysterectomy for the purpose of uterus transplant into a woman with AUFI. Deceased donors will be considered and screened with the organ procurement organization Gift of Life Donation Program.

For more information please visit: https://clinicalresearch.itmat.upenn.edu/clinicaltrial/4821/congenital-abnormalitiesfemale-infertility-penn-ut/

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Mayer Rokitansky Kuster Hauser Syndrome
  • Uterine Agenesis
  • Infertility, Female, of Uterine Origin
  • Uterine Factor Infertility
Intervention  ICMJE Other: Uterine Transplant
Transplant of a uterus from a donor, deceased or living
Other Name: Donor Uterine Transplant
Study Arms  ICMJE Experimental: Uterine Transplantation
Women will undergo extensive medical and psychological screening. Five women that meet all inclusion and exclusion criteria will undergo ovarian stimulation, oocyte retrieval and will create embryos that will be stored for future use. Women will then undergo uterine transplantation from a donor. Following transplant women will be closely monitored for complications (including infection and rejection). If no complications arise, or complications that do arise can be treated, attempts at pregnancy will begin approximately 6 months after transplant. Pregnancy in the setting of uterine transplant requires directly placing embryos directly into the uterus.
Intervention: Other: Uterine Transplant
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Enrolling by invitation
Estimated Enrollment  ICMJE
 (submitted: October 10, 2017)
5
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 1, 2029
Estimated Primary Completion Date July 1, 2029   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Uterine Transplant Recipient Participant Inclusion Criteria:

  1. XX-bearing individual diagnosed with Uterine Factor Infertility (UFI) a
  2. Age 21-40
  3. Lives in Philadelphia region for the duration of the trial
  4. Received counseling regarding alternatives to uterine transplant such as adoption or surrogacy
  5. Intact ovaries
  6. Vaginal length >6 cm (average vaginal length established with dilators)
  7. Body mass index <35 kg/m2
  8. Fluent in the English Language
  9. If cervix present/previously present, human papillomavirus (HPV)) negative or received vaccination for HPV
  10. Willing to comply with screening, protocol and all required procedures
  11. Has adequate social support
  12. Has undergone controlled ovarian hyperstimulation, egg retrieval, in vitro fertilization, and embryo freezing and has frozen embryos of sufficient embryo quality/quantity (≥2 high quality blastocysts); (Required for Transplant Phase, not Screening or Evaluation Phases)

Uterine Transplant Recipient Participant Exclusion Criteria:

  1. Previous multiple major abdominal/pelvic surgery
  2. Severe endometriosis
  3. History of hypertension, diabetes mellitus, thrombophilia or other clotting or bleeding disorders, significant heart, liver, kidney or central nervous system disease
  4. History of prior malignancy except for cervical cancer in stage 1a or 1b (must be in remission for 3 years)
  5. History of significant psychiatric illness
  6. Allergy, hypersensitivity, or intolerance of expected immunosuppressive agents (i.e. Thymoglobulin®, tacrolimus, etc.)
  7. Allergy, hypersensitivity, or intolerance of heparin or aspirin
  8. Presence of active documented systemic infection or recent systemic infection within the past 3 months
  9. Seropositivity for HIV, HBV core antibody or antigen, HCV
  10. Current smoker (smoking cessation must have occurred 3 months prior to enrollment)
  11. Chemical and/or alcohol dependency or abuse
  12. Psychosocial problems (including alcoholism, drug abuse, documented behavioral disorders)
  13. Renal abnormalities, specifically single kidney or pelvic kidneys (imaging confirmation of 2 normal kidneys is required for MRKH subjects)
  14. Contraindications to pregnancy
  15. Unwilling to receive a transfusion of blood or blood products

Living Donor Participant Inclusion Criteria:

  1. Age 30-50
  2. Has definitively completed childbearing
  3. Live birth to miscarriage ratio ≥1
  4. Body mass index <35 kg/m2
  5. Normal uterine anatomy
  6. Normal pap test and Human papillomavirus (HPV) negative
  7. Negative infection screen (HIV, HepB, HepC, Syphilis, gonorrhea, chlamydia)
  8. Received counseling regarding alternatives to uterus donation such as adoption and gestational surrogacy
  9. Fluent in the English Language
  10. Willing to comply with screening, protocol and all required procedures
  11. Has adequate social support
  12. Compatible blood type with recipient
  13. Negative flow cytometric crossmatch with recipient
  14. Has current health insurance
  15. Able to stay in the Philadelphia region for 3 weeks following uterus donation

Living Donor Participant Exclusion Criteria:

  1. Previous multiple major abdominal/pelvic surgery
  2. Severe endometriosis
  3. History of hypertension, diabetes mellitus, thrombophilia or other clotting or bleeding disorders, significant heart, liver, kidney or central nervous system disease
  4. History or obvious evidence of previous multiple/significant uterine surgery. Defined as >1 cesarean delivery and/or myomectomy
  5. History of previous cervical surgery (cone biopsy or loop electrosurgical excision procedure)
  6. Significant systemic disease (diabetes or systemic lupus erythematosus)
  7. Previous obstetric problem including delivery <34 weeks and abnormal placental location (i.e. placenta Previa/accreta/increta/percreta)
  8. Pregnancy
  9. Abnormal uterine cavity
  10. Vascular calcification on imaging tests
  11. History of significant psychiatric illness
  12. Current smoker (smoking cessation must have occurred 3 months prior to enrollment)
  13. Chemical and/or alcohol dependency or abuse
  14. Psychosocial problems (including alcoholism, drug abuse, documented behavioral disorders)
  15. Unwilling to receive a transfusion of blood or blood products
  16. Evidence of coercion or exchange of money or goods for donating the organ

Deceased Donor Inclusion Criteria:

  1. Hemodynamically stable donor
  2. Age between 18 to 50 years
  3. Compatible blood type with recipient
  4. Negative flow cytometric crossmatch with recipient
  5. Live birth to miscarriage ratio ≥1
  6. Normal gross uterine anatomy (as visually assessed by gynecologic surgeon at time of organ procurement)
  7. Macroscopically normal cervix (polyp acceptable)
  8. Negative infection screen (HIV, HepB, HepC, Syphilis)
  9. Cytomegalovirus (CMV)- matched based on rapid donor screening. A CMV positive donor may be used in a CMV negative recipient. A CMV negative donor may be used in either a CMV positive or negative recipient.
  10. Donates after brain death

Deceased Donor Exclusion Criteria:

  1. Current malignancy or history of malignancy active within the past 5 years (Except adequately treated localized basal or squamous cell carcinoma of skin without evidence of recurrence)
  2. No history or obvious evidence of previous multiple/significant uterine surgery. Defined as >1 cesarean delivery and/or myomectomy
  3. No history or obvious evidence of previous cervical surgery (cone biopsy or loop electrosurgical excision procedure)
  4. Significant systemic disease (i.e. diabetes, peripheral vascular or cardiovascular disease, autoimmune disease, renal or liver failure, etc.)
  5. Previous obstetric problem including delivery <34 weeks and abnormal placental location (i.e. placenta Previa/accreta/increta/percreta)
  6. Pregnancy
  7. BMI >35 kg/m2
  8. Donates after cardiac death (DCD)
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Gender Based Eligibility: Yes
Gender Eligibility Description: Female sex; specifically XX-bearing individual
Ages  ICMJE 21 Years to 40 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03307356
Other Study ID Numbers  ICMJE 827853
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Plan Description: Select trial data may be shared with the International Society of Uterine Transplantation (ISUTx) Registry. No protected health information will be shared.
Responsible Party University of Pennsylvania
Study Sponsor  ICMJE University of Pennsylvania
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Kathleen E O'Neill, MD, MTR University of Pennsylvania
PRS Account University of Pennsylvania
Verification Date September 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP